Isoxazole-.beta.-carboline derivatives
    12.
    发明授权
    Isoxazole-.beta.-carboline derivatives 失效
    异恶唑-β-咔啉衍生物

    公开(公告)号:US4933345A

    公开(公告)日:1990-06-12

    申请号:US237368

    申请日:1988-08-29

    CPC分类号: C07D471/04

    摘要: .beta.-Carbolines of general Formula I ##STR1## wherein Y represents the residue ##STR2## and R.sup.a and R.sup.b, being identical or different, mean respectively hydrogen, C.sub.1-6 -alkoxy, phenyl, C.sub.3-7 -cyclo-alkyl, optionally substituted C.sub.1-6 -alkyl or C.sub.1-6 -alkoxycarbonyl, and R.sup.c and R.sup.d, being identical or different, mean respectively hydrogen or C.sub.1-6 -alkyl or jointly a linkage, andR.sup.4 is hydrogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy-C.sub.1-6 -alkyl andR.sup.5 is hydrogen, halogen, OR.sup.6, NR.sup.7 R.sup.8 or CH R.sup.9 R.sup.10 wherein R.sup.6 means C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl or an optionally substituted aralkyl, aryl or hetaryl residue, R.sup.7 and R.sup.8, being identical or different, represent hydrogen, C.sub.1-6 -alkyl, C.sub.3-6 -alkenyl, or jointly with the nitrogen atom a saturated heterocyclic five- or six-membered ring which optionally contains a further hetero atom, R.sup.9 means hydrogen or C.sub.1-6 -alkyl, R.sup.10 means hydrogen, C.sub.1-6 -alkyl, OR.sup.11 or NR.sup.12 R.sup.13 wherein R.sup.11 means C.sub.1-6 -alkyl, R.sup.12 and R.sup.13 are identical or different and mean hydrogen, C.sub.1-6 -alkyl or jointly with the nitrogen atom a saturated heterocyclic five- or six-membered ring optionally containing a further hetero atom, are useful to treat epilepsy or anxiety.

    摘要翻译: 其中Y表示残基,且R a和R b相同或不同,分别表示氢,C 1-6 - 烷氧基,苯基,C 3-7 - 环烷基, 任选取代的C 1-6 - 烷基或C 1-6 - 烷氧基羰基,R c和R d相同或不同,分别表示氢或C 1-6 - 烷基或联合键,并且R 4是氢,C 1-6 - 烷基或C 1 - R6-烷氧基-C1-6-烷基,R5为氢,卤素,OR6,NR7R8或CH R9R10,其中R6表示C1-6烷基,C3-7-环烷基或任选取代的芳烷基,芳基或杂芳基,R7和 R8相同或不同,表示氢,C 1-6 - 烷基,C 3-6 - 烯基,或与氮原子一起为饱和杂环五元或六元环,任选地含有另外的杂原子,R9表示氢或 C 1-6 - 烷基,R 10表示氢,C 1-6 - 烷基,OR 11或NR 12 R 13,其中R 11表示C 1-6 - 烷基,R 12和R 13相同或不同,表示氢,C 1-6 - 烷基或联合 氮原子饱和的杂环五或六元环任选地含有另外的杂原子,可用于治疗癫痫或焦虑。

    Tetrahydro-beta-carbolines, and their use as drugs
    14.
    发明授权
    Tetrahydro-beta-carbolines, and their use as drugs 失效
    四氢-β-咔啉,它们用作药物

    公开(公告)号:US4855295A

    公开(公告)日:1989-08-08

    申请号:US915357

    申请日:1986-10-06

    CPC分类号: C07D471/04

    摘要: 5,6,7,8-tetrahydro-beta-carbolines derivatives of formula I ##STR1## wherein R.sup.1 is an oxadiazolyl radical of the formula ##STR2## COOR.sup.3 or CONR.sup.4 R.sup.5, R.sup.2 is H, lower alkyl or cycloalkyl,R.sup.3 is H or lower alkyl,R.sup.4 and R.sup.5 are H or lower alkyl, whereby R.sup.4 and R.sup.5 cannot be hydrogen at the same time, or R.sup.4 and R.sup.5 together with the adjacent nitrogen atom form a 5- or 6-member ring, which additionally can contain a heteroatom, andR.sup.A is hydrogen, .dbd.O, cycloalkyl, --COOR.sup.3 with R.sup.3 having the above-mentioned meanings, or lower alkyl, which optionally can be substituted by OH, halogen, lower alkoxy, phenyl, phenyloxy, --NR.sup.4 R.sup.5, whereby R.sup.4 and R.sup.5 have the above-mentioned meanings, and R.sup.B can be hydrogen, lower alkyl or lower alkoxyalkyl,have valuable pharmacological properties.

    摘要翻译: 式I的5,6,7,8-四氢-β-咔啉衍生物其中R 1是下式的恶二唑基,COOR 3或CONR 4 R 5,R 2是H,低级烷基或环烷基,R 3是 H或低级烷基,R 4和R 5是H或低级烷基,其中R 4和R 5不能同时为氢,或者R 4和R 5与相邻的氮原子一起形成5-或6-元环,其另外可以含有 杂原子,RA是氢,= O,环烷基,具有上述含义的R 3的-COOR 3或任选被OH,卤素,低级烷氧基,苯基,苯氧基,-NR 4 R 5取代的低级烷基,其中R 4 并且R 5具有上述含义,RB可以是氢,低级烷基或低级烷氧基烷基,具有有价值的药理学性质。

    Phenoxy-substituted beta-carboline derivatives, their production and
their use as drugs
    16.
    发明授权
    Phenoxy-substituted beta-carboline derivatives, their production and their use as drugs 失效
    苯氧基取代的β-咔啉衍生物,其生产和用作药物

    公开(公告)号:US4945090A

    公开(公告)日:1990-07-31

    申请号:US929861

    申请日:1986-11-13

    CPC分类号: C07D471/04

    摘要: Phenoxy-substituted beta-carbolines of the formula I ##STR1## X is COOR.sup.3, CONHC.sub.1-3 -alkyl or oxadiazolyl of the formula ##STR2## R.sup.2 is H, lower alkyl or cycloalkyl, R.sup.3 is lower alkyl,R.sup.4 is hydrogen, lower alkyl or lower alkoxyalkyl,R.sup.1 is hydrogen, halogen, lower alkyl, lower alkoxy, acyl, phenyl, C.sub.2-5 alkylenedioxy, trifluoromethyl, nitrilo, nitro, lower alkoxycarbonyl, azido, SO.sub.2 R.sup.6, SO.sub.2 NR.sup.7 R.sup.8, or NR.sup.9 R.sup.10,R.sup.6 is lower alkyl,R.sup.7 and R.sup.8 independently are lower alkyl or together with the nitrogen atom form a hetero ring,R.sup.9 and R.sup.10 independently are hydrogen, lower alkyl, acyl or together with the nitrogen atom form a hetero ring system,with the proviso that X is not COOEt, if ##STR3## is 5-phenoxy and R.sup.4 is methyl or ##STR4## is 6-(4-methoxyphenoxy) and R.sup.4 is methoxymethyl have valuable pharmacological properties.

    摘要翻译: 式I的苯氧基取代的β-咔啉(I)X是下式的COOR3,CONHC1-3-烷基或恶二唑基,R 2是H,低级烷基或环烷基,R 3是低级烷基,R 4是氢 低级烷基或低级烷氧基烷基,R1为氢,卤素,低级烷基,低级烷氧基,酰基,苯基,C2-5亚烷基二氧基,三氟甲基,次氮基,硝基,低级烷氧基羰基,叠氮基,SO2R6,SO2NR7R8或NR9R10,R6为低级烷基 ,R7和R8独立地是低级烷基或与氮原子一起形成杂环,R9和R10独立地是氢,低级烷基,酰基或与氮原子一起形成杂环体系,条件是X不是COOEt (a)为5-苯氧基,R4为甲基或(b)为6-(4-甲氧基苯氧基),R4为甲氧基甲基具有有价值的药理学性质。

    Diacylapomorphines
    17.
    发明授权

    公开(公告)号:US4080456A

    公开(公告)日:1978-03-21

    申请号:US633650

    申请日:1975-11-20

    CPC分类号: C07D221/18

    摘要: Diacylapomorphines of the formula ##STR1## wherein R.sub.1 and R.sub.2 are both acyl of 1-17 carbons are symptomatically effective agents in the treatment of motor disorders of the type associated with a dopamine deficiency of the extrapyramidal system of the central nervous system, e.g. Parkinson's disease. Pharmaceutical compositions containing these compounds as an active ingredient are described, as well as new compunds of the above formula wherein R.sub.1 and R.sub.2 are formyl or acyl of 3-17 carbon atoms.

    摘要翻译: 其中R 1和R 2都是1-17个碳的酰基的二酰基基吗啡是用于治疗与中枢神经系统的锥体外系统的多巴胺缺乏有关的类型的运动障碍的症状有效的药剂。 帕金森病 描述了含有这些化合物作为活性成分的药物组合物,以及上述式的新型化合物,其中R 1和R 2是3-17个碳原子的甲酰基或酰基。

    Imidazole derivatives
    18.
    发明授权
    Imidazole derivatives 失效
    咪唑衍生物

    公开(公告)号:US4952698A

    公开(公告)日:1990-08-28

    申请号:US189511

    申请日:1988-04-11

    CPC分类号: C07D413/04 C07D233/90

    摘要: Imidazole derivatives of general formula I ##STR1## wherein R.sup.1 represents hydrogen or halogen in the o-, m- or p-position, and the halogen can occur once or repeatedly in the phenyl radical,R.sup.4 represents ##STR2## with R.sup.6 and R.sup.9 representing hydrogen or a straight or branched alkyl group with 1 to 6 carbon atoms, R.sup.7 and R.sup.8 are the same or different and represent hydrogen or a straight or branched alkyl group with 1 to 6 carbon atoms or R.sup.7 and R.sup.8 together with the nitrogen atom represent a saturated heterocyclic five-membered or six-membered ring optionally containing another heteroatom, andR.sup.5 represents hydrogen, an alkyl group with 1 to 6 carbon atoms or an alkoxyalkyl group with 1 to 6 carbon atoms, which are suitable as psychopharmaceuticals, are described.

    摘要翻译: PCT No.PCT / DE87 / 00342 Sec。 371日期:1988年4月11日 102(e)日期1988年4月11日PCT提交1987年7月30日PCT公布。 公开号WO88 / 01268 PCT 日期:1988年2月25日。通式I的咪唑衍生物其中R 1表示氢或卤素在邻 - ,间或对 - 位和卤素可以在苯基中一次或重复出现, R 4表示,其中R 6和R 9表示氢或具有1至6个碳原子的直链或支链烷基,R 7和R 8相同或不同,表示氢或具有1至6个碳原子的直链或支链烷基 碳原子或R 7和R 8与氮原子一起表示任选含有其它杂原子的饱和杂环五元或六元环,R 5表示氢,具有1至6个碳原子的烷基或具有1至6个碳原子的烷氧基烷基 描述了适合作为心理药物的碳原子。